NIAGEN BIOSCIENCE, INC. Capital Leases, Income Statement, Interest Expense
NIAGEN BIOSCIENCE, INC. (NAGE) reported Capital Leases, Income Statement, Interest Expense of $41.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Expense Statement › Interest Expense
us-gaap:CapitalLeasesIncomeStatementInterestExpense · last filed 2019-03-07
- NIAGEN BIOSCIENCE, INC. capital leases, income statement, interest expense for fiscal 2018 was $41.00K, a 28.07% decline from fiscal 2017.
- NIAGEN BIOSCIENCE, INC. capital leases, income statement, interest expense for fiscal 2017 was $57.00K, a 18.75% increase from fiscal 2016.
- NIAGEN BIOSCIENCE, INC. capital leases, income statement, interest expense for fiscal 2016 was $48.00K, a 22.58% decline from fiscal 2016.
- NIAGEN BIOSCIENCE, INC. capital leases, income statement, interest expense for fiscal 2016 was $62.00K, a 31.91% increase from fiscal 2015.
| Period end | Capital Leases, Income Statement, Interest Expense 12 month |
|---|---|
| 2018-12-31 | $41.00K 10-K · filed 2019-03-07 |
| 2017-12-30 | $57.00K 10-K · filed 2019-03-07 |
| 2016-12-31 | $48.00K 10-K · filed 2018-03-15 |
| 2016-01-02 | $62.00K 10-K · filed 2018-03-15 |
| 2015-01-03 | $47.00K 10-K · filed 2017-03-16 |
| 2013-12-28 | $34.00K 10-K · filed 2016-03-17 |
| 2012-12-29 | $29.01K 10-K · filed 2013-03-29 |
| 2011-12-31 | $32.14K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |